Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

NCT00151060 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Estramustine
DRUG: Etoposide
DRUG: Paclitaxel

Sponsor

University of Michigan Rogel Cancer Center